Allegion (NYSE: ALLE) Reports Q1-2026 Financial Results April 28, 2026 High-Single Digit Revenue Growth for the Enterprise; Affirming FY-2026 Organic Revenue Outlook Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.59, down 7.0% compared with $1.71; Adjusted EPS of $1.80, down 3.2% compared with $1.86 Revenues of $1,033.6 million, up 9.7% on a reported basis and up 2.6% on an organic basis Operating margin of 18.9%, compared with 20.9%; Adjusted operating margin of 21.2%, compared with 22.7%
Janus Henderson to Report First Quarter 2026 Results April 24, 2026 Janus Henderson Group plc (NYSE: JHG) (“Janus Henderson” or the “Company”) will announce its first quarter 2026 results after market close on Friday, May 8, 2026. While the previously announced take-private transaction with Trian Fund Management, L.P. and its affiliated funds, and General Catalyst Group Management, LLC and its affiliated funds remains pending, the Company [...]
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights April 23, 2026 Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements April 23, 2026 Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024); Group net profits of €250.9 million (€211.1 million in 2024). Approval of the proposal to distribute a dividend of €1.35 per share. Approval of the plan for the purchase and/or disposal of treasury shares.
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 2026 April 22, 2026 An evolving macro-environment and a transitioning portfolio mix; Updated 2026 outlook
Arm Announces Earnings Release Date for Fourth Quarter Fiscal Year Ended 2026 April 8, 2026 Arm Holdings plc (NASDAQ: ARM) will report financial results for the fourth quarter of fiscal year 2026 on Wednesday, May 6, 2026, after market close. The company will host a conference call via audio webcast at 14:00 Pacific Time (17:00 Eastern Time / 22:00 British Summer Time) to review its financial results and business outlook. [...]
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth March 27, 2026 Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD [...]
LivaNova to Announce First-Quarter 2026 Results March 25, 2026 LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners [...]
OCP Announces Date of Fourth Quarter and Full Year 2025 Earnings March 25, 2026 OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2025 results on Wednesday, April 1, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers on the OCP Intralinks portal from 9:00 a.m. [...]
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights March 24, 2026 COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4 Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch Phase 2b/3 trial in PTSD initiating, following FDA acceptance of IND application Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028